Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 11 results.
User Information
Export Records
  1. 1.   Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia
  2. Winn, Blake A; Devkota, Laxman; Kuch, Bunnarack; MacDonough, Matthew T; Strecker, Tracy E; Wang, Yifan; Shi, Zhe; Gerberich, Jeni L; Mondal, Deboprosad; Ramirez, Alejandro J; Hamel,Ernest; Chaplin, David J; Davis, Peter; Mason, Ralph P; Trawick, Mary Lynn; Pinney, Kevin G
  3. Journal of natural products. 2020, APR 24; 83(4): 937-954.
  1. 2.   Linked dual-class HIV resistance mutations are associated with treatment failure
  2. Boltz,Valerie; Shao,Wei; Bale,Michael; Halvas, Elias; Luke,Brian; McIntyre, James A.; Schooley, Robert T.; Lockman, Shahin; Currier, Judith S.; Sawe, Fred; Hogg, Evelyn; Hughes, Michael D.; Kearney,Mary; Coffin, John M.; Mellors, John W.
  3. JCI INSIGHT. 2019, OCT 3; 4(19):
  1. 3.   Lack of Effect from a Previous Single Dose of Nevirapine on Virologic and Immunologic Responses After 6 Months of Antiretroviral Regimens Containing Either Efavirenz or Lopinavir-Ritonavir
  2. Dlamini, J. N.; Hu, Z. H.; Somaroo, H.; Highbarger, H. C.; Follmann, D. A.; Dewar, R. L.; Pau, A. K.
  3. Pharmacotherapy. 2011, Feb; 31(2): 158-163.
  1. 4.   A Novel Molecular Mechanism of Dual Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors
  2. Nikolenko, G. N.; Delviks-Frankenberry, K. A.; Pathak, V. K.
  3. Journal of Virology. 2010, May; 84(10): 5238-5249.
  1. 5.   Low Frequency Nonnucleoside Reverse-Transcriptase Inhibitor-Resistant Variants Contribute to Failure of Efavirenz-Containing Regimens in Treatment-Experienced Patients
  2. Halvas, E. K.; Wiegand, A.; Boltz, V. F.; Kearney, M.; Nissley, D.; Wantman, M.; Hammer, S. M.; Palmer, S.; Vaida, F.; Coffin, J. M.; Mellors, J. W.
  3. Journal of Infectious Diseases. 2010, Mar; 201(5): 672-680.
  1. 6.   Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design
  2. Boltz, V. F.; Maldarelli, F.; Martinson, N.; Morris, L.; McIntyre, J. A.; Gray, G.; Hopley, M. J.; Kimura, T.; Mayers, D. L.; Robinson, P.; Mellors, J. W.; Coffin, J. M.; Palmer, S. E.
  3. Journal of Virological Methods. 2010, Mar; 164(1-2): 122-126.
  1. 7.   Cytochrome P4502B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda
  2. Penzak, S. R.; Kabuye, G.; Mugyenyi, P.; Mbamanya, F.; Natarajan, V.; Alfaro, R. M.; Kityo, C.; Formentini, E.; Masur, H.
  3. HIV Medicine. 2007, Mar; 8(2): 86-91.
  1. 8.   Generation and characterization of telomere length maintenance in tankyrase 2-deficient mice
  2. Chiang, Y. J.; Nguyen, M. L.; Gurunathan, S.; Kaminker, P.; Tessarollo, L.; Campisi, J.; Hodes, R. J.
  3. Molecular and Cellular Biology. 2006, MAR; 26(6): 2037-2043.
  1. 9.   Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy
  2. Palmer, S.; Boltz, V.; Maldarelli, F.; Kearney, M.; Halvas, E. K.; Rock, D.; Falloon, J.; Davey, R. T.; Dewar, R. L.; Metcalf, J. A.; Mellors, J. W.; Coffin, J. M.
  3. Aids. 2006, Mar; 20(5): 701-710.
  1. 10.   NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts
  2. Papadopoulou, M. V.; Bloomer, W. D.; Hollingshead, M. G.
  3. Anticancer Research. 2005, MAY-JUN; 25(3B): 1865-1869.
  1. 11.   Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice
  2. Papadopoulou, M. V.; Ji, M.; Ji, X. H.; Bloomer, W. D.; Hollingshead, M. G.
  3. Cancer Chemotherapy and Pharmacology. 2002 50(6): 501-508.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel